What dalteparin dose should be used for deep vein thrombosis prophylaxis in a 45‑kg adult with normal renal function?

Dalteparin Dosing for DVT Prophylaxis in a 45 kg Adult

For a 45 kg adult with normal renal function, administer dalteparin 5,000 IU subcutaneously once daily for DVT prophylaxis. 1, 2

Standard Fixed-Dose Regimen

• The prophylactic dose of dalteparin is fixed at 5,000 IU once daily and is not weight-adjusted, regardless of body weight in patients with normal renal function. 3, 1, 2

• This fixed dosing applies to patients weighing less than 50 kg, including your 45 kg patient, without any dose reduction required. 1

• The FDA-approved prophylactic regimen for medical patients with severely restricted mobility is 5,000 IU subcutaneously once daily. 2

Evidence Supporting Fixed Dosing in Low-Weight Patients

• The 2024 European Society of Cardiology consensus statement explicitly confirms that dalteparin 5,000 IU once daily is appropriate for thromboprophylaxis in underweight patients, with no change recommended from standard dosing. 3

• Praxis Medical Insights emphasizes that for patients weighing less than 50 kg with normal renal function, the standard fixed dose of 5,000 IU daily remains appropriate with no dose reduction recommended. 1

• The fixed prophylactic dosing regimen has been validated across diverse patient populations, including those with low body weight, without the need for weight-based adjustments. 1

Clinical Setting-Specific Dosing

Medical Patients (Hospitalized)

• Administer 5,000 IU subcutaneously once daily for the entire hospital stay or until the patient is fully ambulatory. 1, 2

Surgical Patients

• Option 1: Give 2,500 IU 2–4 hours before surgery, followed by 5,000 IU once daily postoperatively. 1, 2
• Option 2: Give 5,000 IU 2–4 hours (or 10–12 hours) before surgery, followed by 5,000 IU once daily. 1, 2
• Continue prophylaxis for a minimum of 7–10 days; extend up to 4 weeks for high-risk surgical patients. 1, 2

Cancer Outpatients

• For select high-risk cancer outpatients, 5,000 IU subcutaneously once daily may be considered. 1

Safety Data in Low-Weight Patients

• No bioaccumulation occurs with the 5,000 IU daily prophylactic dose, even in critically ill patients with severe renal insufficiency (creatinine clearance <30 mL/min). 4

• In a study of 120 patients receiving dalteparin 5,000 IU daily, trough anti-Xa levels remained undetectable (<0.10 IU/mL) with peak levels of only 0.29–0.34 IU/mL, well below therapeutic ranges. 4

• The fixed prophylactic dose of 5,000 IU once daily has been shown effective and safe in elderly patients (including those ≥75 years) without increased bleeding risk. 5, 6

Monitoring Recommendations

• Routine anti-Xa monitoring is not required for prophylactic dosing in patients with normal renal function, regardless of body weight. 1

• Laboratory monitoring should only be considered if severe renal impairment develops (creatinine clearance <30 mL/min) or if bleeding complications occur. 1, 2

Critical Distinction: Prophylactic vs. Therapeutic Dosing

• Do not confuse prophylactic dosing (5,000 IU once daily) with therapeutic dosing (200 IU/kg once daily or 100 IU/kg twice daily), which is weight-based and used for treatment of established VTE. 1, 2

• For a 45 kg patient, therapeutic dosing would be 9,000 IU once daily (200 IU/kg), which is nearly double the prophylactic dose and inappropriate for prophylaxis. 2

Renal Function Considerations

• In patients with severe renal impairment (creatinine clearance <30 mL/min), the 5,000 IU daily prophylactic dose remains acceptable, though monitoring peak anti-Xa levels may be considered for therapeutic dosing. 1, 2

• Pharmacokinetic studies demonstrate no drug accumulation with prophylactic dosing even in patients requiring hemodialysis. 4